Pharmacokinetics-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612

被引：0
|
作者：
Birnberg, T. [1 ]
Adar, L. [1 ]
Poewe, W. [2 ]
Nyholm, D. [3 ]
Bjornsson, M. [4 ]
Karlsson, M. [4 ]
机构：
[1] NeuroDerm, Rehovot, Israel
[2] Med Univ Innsbruck, Innsbruck, Austria
[3] Uppsala Univ, Uppsala, Sweden
[4] Pharmetheus, Uppsala, Sweden
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-363
引用
收藏
页码：608 / 608
页数：1
相关论文
共 50 条
  • [41] Continuous Subcutaneous Levodopa/Carbidopa Infusion With ND0612 For Patients With Parkinson's Disease And Motor Fluctuations: Results From The Phase 3 Randomized, Active-Controlled BouNDless Study
    Rascol, O.
    Albanese, A.
    Ellenbogen, A.
    Ferreira, J.
    Giladi, N.
    Gurevich, T.
    Hassin-Baer, S.
    Hernandez-Vara, J.
    Isaacson, S.
    Kieburtz, K.
    LeWitt, P.
    Lopez-Manzanares, L.
    Olanow, C. W.
    Pahwa, R.
    Poewe, W.
    Sarva, H.
    Stocchi, F.
    Yardeni, T.
    Adar, L.
    Salin, L.
    Lopes, N.
    Sasson, N.
    Case, R.
    Espay, A.
    MOVEMENT DISORDERS, 2023, 38 : S4 - S4
  • [42] Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study
    Isaacson, S.
    Poewe, W.
    Simuni, T.
    Rosenfeld, O.
    Case, R.
    Yardeni, T.
    Olanow, W.
    MOVEMENT DISORDERS, 2020, 35 : S401 - S401
  • [43] Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Data from patients who continued past one year in the BeyoND study
    Isaacson, S.
    Giladi, N.
    Stocchi, F.
    Salin, L.
    Vostokova, N.
    Poewe, W.
    MOVEMENT DISORDERS, 2022, 37 : S334 - S334
  • [44] BouNDless: An active-controlled, randomised, double-blind, double-dummy trial of continuous subcutaneous infusion of levodopa/carbidopa with ND0612 in patients with Parkinson's disease experiencing motor complications
    Rascol, O.
    Poewe, W.
    Stocchi, F.
    Yardeni, T.
    Adar, L.
    Rosenfeld, O.
    Olanow, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 1105 - 1105
  • [45] Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial
    Espay, Alberto J.
    Stocchi, Fabrizio
    Pahwa, Rajesh
    Albanese, Alberto
    Ellenbogen, Aaron
    Ferreira, Joaquim J.
    Giladi, Nir
    Gurevich, Tanya
    Hassin-Baer, Sharon
    Hernandez-Vara, Jorge
    Isaacson, Stuart H.
    Kieburtz, Karl
    Lewitt, Peter A.
    Lopez-Manzanares, Lydia
    Olanow, C. Warren
    Poewe, Werner
    Sarva, Harini
    Yardeni, Tami
    Adar, Liat
    Salin, Laurence
    Lopes, Nelson
    Sasson, Nissim
    Case, Ryan
    Rascol, Olivier
    LANCET NEUROLOGY, 2024, 23 (05) : 465 - 476
  • [46] Administration of continuous subcutaneous carbidopa improves levodopa pharmacokinetics
    Yacoby-Zeevi, O.
    Oren, S.
    LeWitt, P.
    MOVEMENT DISORDERS, 2011, 26 : S284 - S284
  • [47] Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease
    Mueller, Thomas
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (05) : 403 - 414
  • [48] Efficacy and safety of subcutaneous L-dopa/carbidopa (ND0612H) infusion in fluctuating PD patients
    Olanow, C. Warren
    Stocchi, Fabrizio
    Poewe, Werner
    Ellenbogen, Aaron
    Djaldetti, Ruth
    Minei, Tami Rachmilewitz
    Cohen, Yael
    Oren, Sheila
    Kieburtz, Karl
    NEUROLOGY, 2018, 90
  • [49] Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion
    Rosebraugh, Matthew
    Liu, Wei
    Neenan, Melina
    Facheris, Maurizio F.
    JOURNAL OF PARKINSONS DISEASE, 2021, 11 (04) : 1695 - 1702
  • [50] Pharmacokinetics and Pharmacodynamics of Gastroretentive Delivery of Levodopa/Carbidopa in Patients With Parkinson Disease
    Chen, Cuiping
    Cowles, Verne E.
    Sweeney, Michael
    Stolyarov, Igor D.
    Illarioshkin, Sergey N.
    CLINICAL NEUROPHARMACOLOGY, 2012, 35 (02) : 67 - 72
12345